Ani Pharma picks up generic player for a cool $210M, turbocharging its manufacturing and R&D wings
Contract manufacturing work has grown at a rapid clip the past year given demand caused in part by Covid-19. Big players are doubling down on their production footprints, and even small players are taking big swings to get into the game.
Minnesota’s Ani Pharmaceuticals will shell out $89.5 million in cash and $74 million in equity to acquire New Jersey generics player Novitium Pharma, allowing it rapidly scale its manufacturing and R&D infrastructure for generics, the drugmaker said this week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
